Gross Profit Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.

Pharmaceutical Giants: A Decade of Gross Profit Growth

__timestampAmphastar Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 2014512560001055457000
Thursday, January 1, 2015773470001222277000
Friday, January 1, 20161041890001382587000
Sunday, January 1, 2017907950001508505000
Monday, January 1, 20181069850001769378000
Tuesday, January 1, 20191319230002033831000
Wednesday, January 1, 20201433400002214650000
Friday, January 1, 20211997390002653478000
Saturday, January 1, 20222488600003118857000
Sunday, January 1, 20233511210003398627000
Loading chart...

Cracking the code

Gross Profit Growth: A Tale of Two Pharmaceuticals

In the competitive landscape of pharmaceuticals, Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc. have shown remarkable growth in gross profit over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has consistently outperformed Amphastar, with its gross profit growing by over 220%, reaching a peak in 2023. Amphastar, while trailing, has also demonstrated impressive growth, with its gross profit increasing by nearly 590% during the same period.

Jazz Pharmaceuticals' strategic focus on innovative therapies has propelled its financial success, while Amphastar's commitment to affordable medications has driven its steady rise. The data reveals a compelling narrative of growth and resilience, highlighting the dynamic nature of the pharmaceutical industry. As these companies continue to evolve, their financial trajectories offer valuable insights into the broader market trends and the potential for future advancements.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025